Community Trust & Investment Co. Lowers Stake in Zoetis Inc. $ZTS

Community Trust & Investment Co. trimmed its position in Zoetis Inc. (NYSE:ZTS) by 73.3% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,914 shares of the company’s stock after selling 85,005 shares during the quarter. Community Trust & Investment Co.’s holdings in Zoetis were worth $2,221,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Prosperity Bancshares Inc purchased a new position in Zoetis in the fourth quarter valued at approximately $25,000. Cassaday & Co Wealth Management LLC purchased a new stake in Zoetis during the first quarter worth approximately $28,000. Root Financial Partners LLC increased its position in shares of Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after acquiring an additional 103 shares in the last quarter. Elyxium Wealth LLC acquired a new stake in shares of Zoetis in the fourth quarter worth $32,000. Finally, Wellington Grp LLC raised its stake in shares of Zoetis by 6,675.0% in the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after acquiring an additional 267 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently weighed in on ZTS. Stifel Nicolaus reduced their target price on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a report on Friday, June 26th. HSBC reduced their price objective on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. JPMorgan Chase & Co. lowered their target price on Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday. William Blair reiterated a “market perform” rating on shares of Zoetis in a report on Thursday. Finally, Morgan Stanley set a $85.00 price target on Zoetis in a research report on Friday. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $115.50.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, above the $1.84–$1.85 analyst consensus and up from $1.76 a year earlier. The earnings beat provides some support for the stock. Zoetis Surpasses Q2 Earnings Estimates
• Positive Sentiment: JPMorgan lowered its price target from $130 to $115 but maintained an Overweight rating, implying substantial potential upside from recent levels. The target reduction reflects more conservative estimates rather than a bearish long-term view.
• Neutral Sentiment: Zoetis appointed James “Jay” Saccaro as executive vice president and chief financial officer, with the announcement also describing an expanded finance and operating leadership role. The change may improve execution, but its near-term effect on results is unclear. Zoetis Appoints Jay Saccaro
• Negative Sentiment: Second-quarter revenue was $2.47 billion, below the $2.50 billion consensus and essentially flat year over year. Management cited weaker veterinary traffic, customer price sensitivity and competitive pressure in companion-animal products, with promotions being used to defend market share. ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
• Negative Sentiment: Zoetis cut fiscal 2026 guidance to adjusted EPS of $6.15–$6.25 from expectations near $6.87, and revenue guidance to $9.1–$9.3 billion versus consensus of roughly $9.8 billion. The outlook reduction is the primary reason the stock has declined despite the quarterly earnings beat. Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut

Zoetis Stock Performance

NYSE:ZTS opened at $72.53 on Friday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The firm has a 50-day moving average of $76.66 and a two-hundred day moving average of $100.75. The stock has a market cap of $30.41 billion, a P/E ratio of 11.95, a PEG ratio of 1.34 and a beta of 0.74. Zoetis Inc. has a 1-year low of $71.47 and a 1-year high of $160.48.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 70.95% and a net margin of 27.49%.The business had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same period in the previous year, the company earned $1.76 earnings per share. The company’s revenue for the quarter was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, research analysts expect that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.9%. Zoetis’s payout ratio is currently 35.16%.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Paul Bisaro bought 2,000 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the transaction, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Frank A. Damelio purchased 6,650 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were bought at an average cost of $75.39 per share, with a total value of $501,343.50. Following the transaction, the director directly owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 11,650 shares of company stock valued at $886,384 in the last three months. Corporate insiders own 0.22% of the company’s stock.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.